On March 7, 2018 Amgen (NASDAQ:AMGN) reported its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019, to all stockholders of record as of the close of business on May 17, 2019 (Press release, Amgen, MAR 7, 2019, View Source;p=RssLanding&cat=news&id=2390572 [SID1234534167]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 7, 2019 Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, reported the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $17.00 per share, for total gross proceeds of $102 million, before deducting underwriting discounts and commissions and expenses payable by Apellis (Press release, Apellis Pharmaceuticals, MAR 7, 2019, View Source [SID1234534062]). All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on March 11, 2019, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citigroup, J.P. Morgan and Cowen are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is acting as lead manager for the offering.

The shares are being offered by Apellis pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission ("SEC") on December 28, 2018 and amended on February 26, 2019. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (631) 274-2806.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On March 7, 2019 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that members of the Company’s management team will participate at several upcoming conferences (Press release, Atara Biotherapeutics, MAR 7, 2019, View Source [SID1234534078]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 39th Annual Health Care Conference

Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will give a presentation on Tuesday, March 12, 2019 at 10:00 a.m. EDT. The conference will be held at the Boston Marriott Copley Place in Boston, MA.
Memorial Sloan Kettering 3rd Annual Clinical Application of CAR T Cells Conference

Chris Haqq, M.D., Ph.D., the Company’s Executive Vice President of Research and Development and Chief Scientific Officer, will participate in the Industry Session on Thursday, March 14, 2019 at 4:35 p.m. EDT. The conference will be held at the Zuckerman Research Center in New York, NY.
William Blair 9th Annual Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper)

Chris Haqq, M.D., Ph.D., the Company’s Executive Vice President of Research and Development and Chief Scientific Officer, will present on Wednesday, March 20, 2019 at 11:00 a.m. EDT. The conference will be held at the Apella Event Space Alexandria Center in New York, NY.
Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day

Chris Haqq, M.D., Ph.D., the Company’s Executive Vice President of Research and Development and Chief Scientific Officer, will participate in a panel titled "Cell Therapy for Solid Tumors" on Thursday, March 21, 2019 at 1:30 p.m. EDT. The Conference will be held at the Metropolitan Club in New York, NY.
Jefferies 6th Annual IO Cell Therapy Summit

Dietmar Berger, M.D., Ph.D., the Company’s Global Head of Research and Development, will present on Friday, April 5, 2019. The conference will be held at the Boston Harbor Hotel in Boston, MA and the time of the presentation will be available on Atara’s investor events webpage by March 29.
Live audio webcasts of the presentations at the Cowen and Company 39th Annual Health Care Conference and Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day will be available by visiting the Investor Events and Presentations section of the Atara website. An archived replay of each webcast will be available on the Company’s website for 14 days following the conclusion of each presentation.

On March 7, 2019 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") reported that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes (Press release, Aurinia Pharmaceuticals, MAR 7, 2019, View Source [SID1234534124]). Aurinia’s management team will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and to provide a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call and webcast is scheduled for March 19, 2019 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

On March 7, 2019 Amgen (NASDAQ:AMGN) reported that will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston (Press release, Amgen, MAR 7, 2019, View Source;p=RssLanding&cat=news&id=2390558 [SID1234534168]). David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!